We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The FDA has issued final guidance on assessment and control of DNA reactive impurities in harmony with guidance prepared by the International Council for Harmonisation (ICH). Read More
Astellas Pharma announced a $21.3 million research collaboration with PeptiDream to discover novel protein degraders — enzymes that disassemble and break down unneeded proteins — used in cancer treatments. Read More
Despite the catastrophic damage a tornado caused to Pfizer’s colossal sterile injectable drug manufacturing plant and warehouse in Rocky Mount, N.C., last week, FDA Commissioner Robert Califf says he doesn’t expect “immediate significant impacts” on the supply chain. Read More
The European Medicines Agency’s (EMA) human medicines committee (CHMP) recommended 14 medicines for market authorization during its July meeting including GSK’s Apretude (cabotegravir) for HIV, seven cancer treatments and a drug for relapsing multiple sclerosis. Read More
As the 118th Congress continues, FDAnews will track important pending legislation to keep you updated on regulations that could impact your business. Read More
The Senate Health, Education, Labor and Pensions (HELP) Committee has advanced reauthorization of the 2006 Pandemic and All Hazards Preparedness Act (PAHPA), allowing the FDA to require that manufacturers notify the agency of potential product shortages when there’s no public health emergency (PHE). Read More
In an open public meeting, the FTC voted 3-0 Thursday to withdraw comments it has issued over the past 13 years in support of pharmacy benefit managers (PBM) – comments the PBM industry has begun using to defend itself in recent public relations campaigns. Read More
Boehringer-Ingelheim, Eli Lilly and Novo Nordisk have added their support to a bipartisan, bicameral bill — the Treat and Reduce Obesity Act (S. 2407 and H.R. 4818) — to expand Medicare coverage of medications and health care specialists to treat obesity. Read More
The letter points out that approximately 32 percent of generic drugs and 45 percent of active pharmaceutical ingredients are from India and China. Read More